Acasti Pharma Inc., of Laval, Quebec, which is developing its prescription candidate Capre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, said it was awarded up to $750,000 in nondilutive and nonrepayable funding, as well as technical and business advisory services, from the National Research Council of Canada Industrial Research Assistance Program to expand and enhance its production capabilities for Capre.